Opendata, web and dolomites

BRAINSPECT

Ultra high resolution Single Photon Computed Emission Tomography for the molecular imaging of brain disease

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 BRAINSPECT project word cloud

Explore the words cloud of the BRAINSPECT project. It provides you a very rough idea of what is the project "BRAINSPECT" about.

35    disturbed    sound    techniques    route    plaques    market    amongst    commercial    ultra    sme    mentioned    clinical    hallmarks    reconstruction    proprietary    compensates    resolutions    disrupt    pinholes    blood    yield    unprecedented    proven    consuming    accurate    worldwide    regional    indications    insufficient    initial    flow    assessing    instrument    tomography    dose    feasibility    stage    either    diagnosed    figure    patient    prototype    rcbf    spect    emission    cerebral    imbalance    single    stages    computed    uses    mi    parts    characterising    molecular    multiple    resolution    reposition    photon    utility    artefacts    small    patients    brain    software    images    time    disorders    lower    clinicians    validation    radically    progression    measuring    imaging    disease    point    ring    animals    sensitive    movement    shorter    strategy    multibillion    times    costly    modality    sparked    neurotransmitter    complete    milabs    radiation    perfusion    spatial    bandwidth    scan    detection    enthusiasm    isolate    fold   

Project "BRAINSPECT" data sheet

The following table provides information about the project.

Coordinator
MILABS BV 

Organization address
address: Heidelberglaan 100 STR. 4.105
city: Utrecht
postcode: 3584 CX
website: www.milabs.com

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Netherlands [NL]
 Project website http://www.milabs.com/g-spect/
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-1-2014
 Funding Scheme SME-1
 Starting year 2015
 Duration (year-month-day) from 2015-05-01   to  2015-10-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    MILABS BV NL (Utrecht) coordinator 50˙000.00

Map

 Project objective

MILabs’ radically new proprietary approaches for ultra-high resolution and ultra-sensitive brain SPECT (Single Photon Emission Computed Tomography) enable the measuring of disturbed regional cerebral blood flow (rCBF) perfusion, and characterising plaques and neurotransmitter imbalance - all important hallmarks of brain disorders - at unprecedented spatial resolutions. This new approach has the potential to disrupt the complete field of molecular imaging (MI), a multibillion market worldwide. Current techniques can only measure the mentioned effects in the brain either at late stages of disease progression (at which point the patients have already been diagnosed) or at insufficient resolution to isolate processes in small parts of the brain. Current SPECT results in low resolution images, are highly sensitive to patient movement and are time consuming and costly. MILabs has developed a clinical SPECT prototype, G-SPECT, which has proven its potential to reposition SPECT as the major clinical MI modality. G-SPECT uses a high bandwidth photon detection ring with multiple pinholes, and advanced reconstruction software that compensates for patient movement artefacts. This enables 35-fold higher resolution images, more accurate imaging and lower radiation dose due to shorter scan times (Figure 1). The application of MILabs SPECT technology in small animals has sparked enthusiasm amongst clinicians and brain researchers worldwide. In this Stage 1 SME Instrument, MILabs will investigate the commercial feasibility of this exciting technology by (i) identifying and assessing those indications to which the clinical utility yield the best initial market value, (ii) developing a sound clinical validation strategy and (iii) defining the route-to-market.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "BRAINSPECT" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "BRAINSPECT" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

PanCareFollowUp (2019)

PanCareFollowUp: Novel, patient-centred survivorship care to improve care quality, effectiveness, cost-effectiveness and accessibility for survivors and caregivers

Read More  

ENDOSCAPE (2019)

ENDOSCAPE, a clinically applicable non-viral gene delivery technology

Read More  

INTE-AFRICA (2019)

Integrating and decentralising diabetes and hypertension services in Africa

Read More